My watch list
my.chemeurope.com  

my.chemeurope.com

With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.

  • My watch list
  • My saved searches
  • My saved topics
  • My newsletter
Register free of charge
Login  
eng  
DeutschEnglishFrançaisEspañol

Elvitegravir



Elvitegravir (EVG) is an investigational drug for the treatment of HIV. It acts as an integrase inhibitor. It is undergoing clinical trials conducted by the pharmaceutical company Japan Tobacco.[1][2]

According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.[3]

References

  1. ^ Shimura K, Kodama E, Sakagami Y, et al (2007). "Broad Anti-Retroviral Activity and Resistance Profile of a Novel Human Immunodeficiency Virus Integrase Inhibitor, Elvitegravir (JTK-303/GS-9137)". J Virol. doi:10.1128/JVI.01534-07. PMID 17977962.
  2. ^ Stellbrink HJ (2007). "Antiviral drugs in the treatment of AIDS: what is in the pipeline ?". Eur. J. Med. Res. 12 (9): 483–95. PMID 17933730.
  3. ^ Thaczuk, Derek and Carter, Micheal. ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents Aidsmap.com. 19 Sept. 2007.
v • d • e
Antivirals used against HIV (HAART) (primarily J05)
Nucleoside & Nucleotide
Reverse Transcriptase Inbitors (NRTI)		Abacavir (ABC) • Didanosine • Emtricitabine° • Lamivudine (3TC)° • Stavudine • Zidovudine (AZT)° • Tenofovir° • Apricitabine† • Stampidine† • Elvucitabine† • Racivir† • Zalcitabine‡
Non-Nucleoside
Reverse Transcriptase Inhibitiors (NNRTI)		Efavirenz° • Nevirapine • Etravirine† • Rilpivirine† • Loviride‡ • Delavirdine‡
Protease Inhibitors (PI)Atazanavir • Darunavir • Fosamprenavir • Lopinavir° • Nelfinavir • Ritonavir • Saquinavir • Tipranavir • Amprenavir‡ • Indinavir‡
Entry/fusion inhibitorsEnfuvirtide • Maraviroc • Vicriviroc† • PRO 140†
Integrase inhibitorsRaltegravir • Elvitegravir†
Maturation inhibitorsBevirimat† • Vivecon™†
Combined formulationsCombivir • Atripla • Trizivir • Truvada • Kaletra • Epzicom
Other & experimental agentsFoscarnet • Synergistic enhancers • Epigallocatechin gallate • Portmanteau inhibitors • Globoidnan A • Griffithsin • Diarylpyrimidines • Calanolide A
†Undergoing clinical trials, not FDA approved. ‡Formerly or rarely used agent. °Preferred first-line agent.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Elvitegravir". A list of authors is available in Wikipedia.
Last viewed
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE